• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Cluster analysis identifies phenotype groups for atrial fibrillation with unique clinical outcomes

byJames EnglandandAnees Daud
November 21, 2017
in Cardiology, Chronic Disease, Emergency, Imaging and Intervention, Neurology, Public Health, Surgery
Reading Time: 3 mins read
Long-term outcomes for off-pump and on-pump CABG are similar
Share on FacebookShare on Twitter

1. Cluster analysis of a population of patients with atrial fibrillation (AF) identified four unique phenotypes using variables not traditionally associated with AF classification.

2. The four phenotypic AF groups were associated with differences in treatment strategies and clinical outcomes.

Evidence Rating Level: 3 (Average)    

Study Rundown: Atrial fibrillation is the most common cardiac arrhythmia and is associated with significant morbidity. Traditional classification systems have characterized patients based on duration or thromboembolic risk. The current classification systems may not capture the full extent of diversity of AF patients and could fail to encapsulate important variables for disease course. The current study sought to re-evaluate clinical phenotypes of AF by evaluating a study population with cluster variable analysis and determine the connection between phenotype and treatment and clinical outcomes. The analysis determined four phenotypic groupings: a low comorbidity group, young patients with comorbid behavioral disorders, patients requiring device implantation, and those with atherosclerotic disease comorbidities. The study found adverse cardiovascular and neurologic events were more common amongst the 3-comorbidity groups, and major bleeding was more common in the behavioral comorbidity, and device implantation groups.

The study has important significance as it applies a novel statistical approach to describe phenotypic groups of patients with AF which may prove more meaningful that current classification systems. Factors that comprise the current classification of AF were not determined to be significant in the cluster analysis. The study has a large population and was also externally validated in a second large population. The main limitations of the study include the reliance on a set number of available variables, and the influence of existing patterns of care on clinical outcomes.

Click to read the study in JAMA Cardiology

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

2 Minute Medicine Rewind August 31, 2026

Relevant Reading: Clinical Classifications of Atrial Fibrillation Poorly Reflect Its Temporal Persistence: Insights From 1,195 Patients Continuously Monitored With Implantable Devices

In-Depth [prospective cohort]: This study used data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry and included patients 18 years and older with electrographically confirmed AF. Patients with identified reversible causes of AF or life expectancy less than 6 months were excluded. Data on comorbidity and adverse clinical outcomes were obtained at baseline, and then every 6-months up to 2 years. The primary outcome includes a composite of cardiovascular death, myocardial infarction, stroke/non CNS systemic embolism, or transient ischemic attack. Cluster analysis was performed using 60 baseline variables and resulted in the 4-cluster model as described before. External validation was performed using a mutually excluded ORBIT-AF II Registry.

In analysis of treatment patters, patients in the device implantation cluster were more likely to be managed with rate control. Patients in the low comorbidity cluster were more likely to be on a Class 1c antiarrhythmic agent. Compared to the low-comorbidity cluster, the primary outcome was more common in the behavioural (hazard ratio [HR], 1.49; 95%CI, 1.10-2.00), device implantation (HR, 1.39; 95%CI, 1.15-1.68), and atherosclerotic clusters (HR, 1.59; 95%CI, 1.31-1.92). Major bleeding was more common in the behavioural (HR, 1.35; 95%CI, 1.05-1.73), and device implantation clusters (HR, 1.24; 95%CI, 1.05-1.47).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anti-arrhythmicatrial fibrillationtachyarrhythmias
Previous Post

Nonmedical prescription drug use associated with dating violence in adolescents

Next Post

Providing unlimited, immediate access to opioid agonist therapy to people with opioid use disorders could save billions and improve outcomes

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Weekly Rewinds

2 Minute Medicine Rewind August 31, 2026

August 31, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Catheter ablation within 1 year of atrial fibrillation diagnosis is associated with reduced risk of recurrence

July 24, 2026
Next Post
Participation in sports and exercise linked to lower opioid use

Providing unlimited, immediate access to opioid agonist therapy to people with opioid use disorders could save billions and improve outcomes

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

Development of a risk index for colorectal cancer screening

Study suggests testing certain protein combinations can enhance sensitivity of fecal immunochemical test used in colorectal cancer screenings

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deficits in executive function are not universal among patients with alcohol use disorder
  • Choice of bicarbonate-buffered solution versus compound sodium lactate as the intraoperative crystalloid solution during abdominal surgery remains unclear
  • Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.